HCS
IOVA icon

Himension Capital (Singapore)’s Iovance Biotherapeutics IOVA Stock Holding History

Himension Capital (Singapore)’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-13,823
Closed -$437K – 20
2021
Q1 		$437K Hold
13,823
– – 0.09% 16
2020
Q4 		$641K Buy
+13,823
New +$549K 0.22% 16

Other funds holding IOVA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Himension Capital (Singapore)'s IOVA Position: Q2 2021 in Review

Himension Capital (Singapore) sold out of Iovance Biotherapeutics (IOVA) in Q2 2021, closing a stake of 13,823 shares — an estimated $437K sold.

Himension Capital (Singapore) first reported a position in IOVA in Q4 2020 and held it in 2 quarters. The position peaked at $641K in Q4 2020. 234 funds tracked by Wall St. Rank hold IOVA as of Q2 2021.

  • Himension Capital (Singapore) reported no remaining Iovance Biotherapeutics position as of Q2 2021 after selling out during the quarter.
  • Himension Capital (Singapore) sold 13,823 Iovance Biotherapeutics shares in Q2 2021, an estimated $437K.
  • Himension Capital (Singapore) first reported a position in Iovance Biotherapeutics in Q4 2020 and held it in 2 quarters.
  • Himension Capital (Singapore)'s Iovance Biotherapeutics position peaked at $641K in Q4 2020.
  • 234 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2021.

Based on Himension Capital (Singapore)'s 13F filing for Q2 2021, filed 3 Aug 2021.